<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Scleromyxedema</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Scleromyxedema</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Scleromyxedema</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Franco Rongioletti, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H27631275"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Scleromyxedema, also known as diffuse/generalized and sclerodermoid lichen myxedematosus or Arndt-Gottron disease, is a primary cutaneous mucinosis characterized by a generalized, papular and sclerodermoid, cutaneous eruption that usually occurs in association with monoclonal gammopathy [<a href="#rid1">1</a>]. Affected patients develop numerous waxy, firm papules and plaques that demonstrate mucin deposition, increased fibroblast proliferation, and fibrosis on histologic examination. Systemic manifestations may involve the cardiovascular, gastrointestinal, pulmonary, musculoskeletal, renal, or nervous systems and may lead to significant morbidity and mortality.</p><p>Scleromyxedema should be distinguished from localized lichen myxedematosus, a form of lichen myxedematosus that presents with waxy, firm papules and plaques involving limited areas. Unlike scleromyxedema, sclerotic features, systemic involvement, and monoclonal gammopathy are absent in localized lichen myxedematosus. Scleroderma and scleredema are additional disorders that present with sclerodermoid features but are unrelated to scleromyxedema. Scleromyxedema is also distinct from myxedema of thyroid disease. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/110154.html" rel="external">"Localized lichen myxedematosus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/89274.html" rel="external">"Scleredema"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism"</a>.)</p><p></p><p>The clinical features, diagnosis, and management of scleromyxedema will be reviewed here.</p><p class="headingAnchor" id="H27631281"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Scleromyxedema is a rare disease that usually affects middle-aged adults between the ages of 30 and 80 years with no race or sex predominance [<a href="#rid1">1</a>]. In a multicenter, retrospective study of 30 patients with scleromyxedema, the mean age of affected patients was 59 years [<a href="#rid1">1</a>]. This illness is extremely rare in infants and young children.</p><p class="headingAnchor" id="H27631287"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of scleromyxedema is unknown. The significance of the associated monoclonal gammopathy and the underlying plasma cell clone is debated. The main hypothesis is that circulating cytokines, such as interleukin (IL) 1, tumor necrosis factor (TNF)-alpha, and transforming growth factor (TGF)-beta, known to stimulate glycosaminoglycan synthesis and fibroblast proliferation in the skin, could play a role [<a href="#rid2">2-4</a>].</p><p>A promoting role of TGF-beta has also been identified in case series by analysis of RNA in involved skin tissue [<a href="#rid5">5,6</a>]. New insights were added by a study in which abnormally high secretion of IL-4, a profibrotic cytokine, was found in serum from scleromyxedema patients, suggesting a chronic Th2-skewed T cell response against an unknown target antigen [<a href="#rid7">7</a>]. The same study also found that both CD4+ and CD8+ T cells from patients with scleromyxedema present a profound deficiency (even after stimulation) of the production of interferon-gamma and IL-17 with respect to healthy donor control cells. Involvement of interferon pathways has been previously suggested, and the role of interferon-gamma in scleromyxedema could be related to the lack of its inhibitory effect on both proliferation and extracellular matrix production by fibroblasts.</p><p>Clinical remission of scleromyxedema following autologous stem cell transplantation suggests that the bone marrow may be a source of these circulating factors [<a href="#rid2">2,8</a>]. (See <a class="local">'Severe and refractory disease'</a> below.)</p><p>Many authors have also suggested that paraproteins themselves may be pathogenic, acting as autoantibodies that stimulate fibroblasts to proliferate and overproduce mucin. However, data conflict on the relevance of this theory. Although serum isolated from patients with scleromyxedema has enhanced fibroblast proliferation in some in vitro studies [<a href="#rid9">9,10</a>], one of these studies also found that purified immunoglobulin from the serum did not stimulate fibroblast growth [<a href="#rid9">9</a>]. In addition, a study in which serum from a patient with scleromyxedema was found to increase production of hyaluronic acid (a component of mucin) and prostaglandin E by fibroblast cultures did not find a stimulatory effect of the serum on fibroblast proliferation [<a href="#rid11">11</a>]. Moreover, paraprotein levels usually do not correlate with the severity of disease, disease progression, or the response to treatment [<a href="#rid1">1</a>]. Only on anecdotal basis has the complete resolution of skin lesions coincided with the normalization of the bone marrow and the disappearance of the paraprotein [<a href="#rid12">12</a>].</p><p>Additional theories on the pathogenesis of scleromyxedema have been proposed. It has been suggested that an intrinsic abnormality of scleromyxedema fibroblasts may result in increased glycosaminoglycan synthesis [<a href="#rid13">13</a>]. In addition, case reports documenting the development of scleromyxedema following a cutaneous, granulomatous reaction after intradermal hyaluronic gel injections [<a href="#rid14">14</a>] or after breast silicone implantation [<a href="#rid1">1</a>] may suggest a type of autoimmune syndrome induced by adjuvants.</p><p class="headingAnchor" id="H27631293"><span class="h1">CLINICAL FINDINGS</span><span class="headingEndMark"> — </span>The clinical manifestations of scleromyxedema include both cutaneous and extracutaneous features.</p><p class="headingAnchor" id="H27631301"><span class="h2">Cutaneous manifestations</span><span class="headingEndMark"> — </span>The characteristic skin finding in scleromyxedema is a widespread eruption of 2 to 3 mm, firm, waxy, closely spaced, dome-shaped or flat-topped papules involving the hands, forearms, head, neck, upper trunk, and thighs  (<a class="graphic graphic_picture graphicRef91117 graphicRef91118" href="/z/d/graphic/91117.html" rel="external">picture 1A-B</a>) [<a href="#rid2">2,3</a>]. Papules are often arranged in a strikingly linear array, and the surrounding skin is shiny and indurate (ie, sclerodermoid) in appearance  (<a class="graphic graphic_picture graphicRef91119" href="/z/d/graphic/91119.html" rel="external">picture 2</a>). Rarely, nontender subcutaneous nodules are present. The glabella is typically involved with deep, longitudinal furrows that produce the characteristic leonine face  (<a class="graphic graphic_picture graphicRef91120" href="/z/d/graphic/91120.html" rel="external">picture 3</a>). Deep furrowing also is typically evident on the trunk or limbs associated with redundant skin folds (known as "Shar-Pei sign")  (<a class="graphic graphic_picture graphicRef91121" href="/z/d/graphic/91121.html" rel="external">picture 1C</a>). Erythema, edema, and a brownish discoloration may be seen in the involved areas; pruritus is not uncommon. </p><p>Eyebrow, axillary, and pubic hair may be sparse in patients with scleromyxedema. The mucous membranes are spared. As the condition progresses, erythematous and infiltrated plaques may appear with skin stiffening, sclerodactyly, and decreased motility of the mouth and joints. On the proximal interphalangeal joints, a central depression surrounded by an elevated rim (due to skin thickening) can be seen and is referred to as the "doughnut sign"  (<a class="graphic graphic_picture graphicRef91122" href="/z/d/graphic/91122.html" rel="external">picture 4</a>). Unlike scleroderma, telangiectasias and calcinosis are absent. Although rare, the Raynaud phenomenon occurs.</p><p class="headingAnchor" id="H27631307"><span class="h2">Extracutaneous manifestations</span><span class="headingEndMark"> — </span>Patients with scleromyxedema can have a number of internal manifestations, including neurologic, rheumatologic, cardiovascular, gastrointestinal, pulmonary, and renal manifestations of the disease. In a multicenter, retrospective study of 30 patients with scleromyxedema, the most common extracutaneous manifestations were neurologic abnormalities (30 percent of patients), rheumatologic abnormalities (25 percent of patients), and cardiac abnormalities (22 percent of patients) [<a href="#rid1">1</a>]. In a retrospective study of 33 patients with scleromyxedema from France, the most frequent complications were carpal tunnel syndrome and arthralgia, occurring in 33 and 27 percent of patients, respectively [<a href="#rid5">5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic </strong>–<strong> </strong>Neurologic complications may involve the peripheral nervous system (eg, carpal tunnel syndrome or peripheral sensory and motor neuropathy) or the central nervous system (eg, memory loss, vertigo, gait problems, stroke, seizures, psychosis, or "dermato-neuro syndrome") [<a href="#rid5">5,15,16</a>]. Carpal tunnel syndrome is thought to be due to either deposition of glycosaminoglycans in the carpal tunnel or to a direct toxic effect in the median nerve [<a href="#rid17">17</a>]. The dermato-neuro syndrome is an occasionally lethal, acute, neurologic complication characterized by fever, confusion, dysarthria, lethargy, convulsions, and coma [<a href="#rid16">16,18</a>]. The dermato-neuro syndrome often is preceded by flu-like symptoms. In the French series, 18 percent of patients had dermato-neuro syndrome [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rheumatologic </strong>–<strong> </strong>Rheumatologic manifestations are characterized by arthralgias or arthritis of the peripheral joints, especially of the hands, with noninflammatory synovial fluids [<a href="#rid19">19</a>]. A severe, destructive polyarthritis resembling rheumatoid arthritis also has been reported [<a href="#rid20">20</a>]. Proximal or generalized weakness due to inflammatory myopathy and fibromyalgia is common and usually occurs several months or years after the onset of skin involvement [<a href="#rid4">4,21</a>]. In these patients, muscle biopsy reveals a necrotizing and vacuolar myopathy; interstitial inflammatory infiltrates are found uncommonly and may cause confusion with polymyositis. A few cases of true dermatomyositis have been described in association with scleromyxedema [<a href="#rid22">22</a>]. Spontaneous or interferon alfa-induced rhabdomyolysis is an additional rare finding [<a href="#rid23">23,24</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular </strong>–<strong> </strong>Cardiovascular abnormalities with congestive heart failure, myocardial ischemia, heart block, and pericardial effusion may occur [<a href="#rid1">1,25,26</a>]. Valvular mucin deposition has been described in a case report [<a href="#rid27">27</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal </strong>– Dysphagia is the most common gastrointestinal manifestation and is related to esophageal dysmotility mainly localized to the upper esophagus [<a href="#rid28">28</a>]. Dysphagia is most commonly found in patients with an associated myopathy. Nasal regurgitation may also occur [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory </strong>–<strong> </strong>Dyspnea on exertion is the most common pulmonary finding, due to obstructive or restrictive pathology [<a href="#rid28">28-30</a>]. In addition, hoarseness and aspiration may occur due to laryngeal involvement with decreased epiglottis and vocal cord mobility [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal </strong>– Involvement of the kidney, characterized by a scleroderma renal crisis-like acute renal failure, is a rare event [<a href="#rid32">32</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocular </strong>– Infrequently, corneal opacities and ectropion are seen. </p><p></p><p>The pathogenesis of the extracutaneous manifestations of scleromyxedema is unclear. It has been suggested that mucin deposition in various organs may be the cause, although mucin is not consistently found on autopsy in fatal cases [<a href="#rid33">33,34</a>].</p><p>In dermato-neuro syndrome, brain autopsy has not been contributory, and the pathogenic basis of the encephalopathy remains obscure [<a href="#rid16">16</a>]. It has been proposed that an increased blood viscosity with impaired microcirculation due to paraproteinemia may result in encephalopathy. A pathogenic role for immunoglobulin G (IgG) crossing a damaged blood-brain barrier, mediated by increased interleukin (IL) 6 production, has also been suggested [<a href="#rid16">16,35</a>]. Some authors have proposed viral infection-associated elevation of IL-6 as a contributing factor. Supportive observations include the frequent association of the syndrome with a flu-like prodrome or upper respiratory infection symptoms and reports of the onset of dermato-neuro syndrome in conjunction with influenza or coronavirus disease 2019 (COVID-19) [<a href="#rid36">36-38</a>].</p><p class="headingAnchor" id="H193080025"><span class="h1">ASSOCIATED DISORDERS</span><span class="headingEndMark"> — </span>Scleromyxedema is usually associated with monoclonal gammopathy. The monoclonal protein is most commonly IgG-lambda [<a href="#rid1">1,5,28,29</a>]. However, less frequently, a different monoclonal protein type is present [<a href="#rid28">28</a>]. Patients with scleromyxedema in the absence of monoclonal gammopathy are considered to have an atypical form of the disease. (See  <a class="medical medical_review" href="/z/d/html/6652.html" rel="external">"Diagnosis of monoclonal gammopathy of undetermined significance"</a> and  <a class="medical medical_review" href="/z/d/html/15772.html" rel="external">"Clinical course and management of monoclonal gammopathy of undetermined significance"</a>.)</p><p>A mild plasmacytosis may be found in the bone marrow of patients with scleromyxedema. However, the disease is estimated to progress to multiple myeloma in less than 10 percent of cases, similar to monoclonal gammopathy of undetermined significance [<a href="#rid4">4</a>]. Anecdotal associations with hematologic malignancies (such as Hodgkin and non-Hodgkin lymphomas, Waldenström macroglobulinemia, lymphoid leukemia, and myelomonocytic leukemia) or visceral carcinomas have been reported [<a href="#rid1">1,39-41</a>]. Although treatment of the primary cancer may result in the regression of the skin lesions, no clear association with any specific noniatrogenic neoplasm has been identified. Most hemolymphoproliferative malignancies in these patients are iatrogenic and associated with the use of <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> treatment [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H27631313"><span class="h1">CLINICAL COURSE</span><span class="headingEndMark"> — </span>Scleromyxedema follows a chronic, progressive, and sometimes unpredictable course [<a href="#rid3">3</a>]. Depending on the rapidity of onset and the degree of involvement, patients may be either initially asymptomatic or may notice that skin becomes thick and hard and that the face shows a diffuse induration and coarsening in the forehead lines and in lateral portions of the chin. As the disease progresses (usually over the course of years and, occasionally, over the course of several months), a diffuse, sclerodermoid induration with overlying papules, sclerodactyly, and decreased motility of the mouth and joints occurs. Our experience suggests that spontaneous resolution does not occur; however, at least one case of apparent spontaneous resolution has been reported [<a href="#rid42">42</a>].</p><p>Systemic consequences of scleromyxedema may result in death [<a href="#rid1">1,33</a>]. In a case series in which follow-up was available for 21 patients with scleromyxedema (mean follow-up time 33.5 months, range 2 months to 11 years), at the end of follow-up, 5 patients (23.8 percent) died, whereas 12 patients were alive with disease and 4 patients were alive without disease [<a href="#rid1">1</a>]. Death was caused by extracutaneous complications of scleromyxedema, including dermato-neuro syndrome (two patients) and myocardial insufficiency due to endocardial mucin deposition (one patient) or by an associated myeloid leukemia (one patient) or Hodgkin lymphoma (one patient). A better prognosis was reported in a French study in which the overall survival of all 33 patients with scleromyxedema was 97 percent at three years [<a href="#rid5">5</a>].</p><p>Death also may occur as a side effect of treatment. In particular, treatment with <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> has been associated with death from complications of sepsis and hematologic malignancies [<a href="#rid28">28</a>]. In the French study, one patient died of severe sepsis and specific heart involvement following chemotherapy treatment with <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, melphalan, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H27631339"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Scleromyxedema is characterized by a triad of microscopic features that includes  (<a class="graphic graphic_picture graphicRef91123 graphicRef91124" href="/z/d/graphic/91123.html" rel="external">picture 5A-B</a>) [<a href="#rid43">43,44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A diffuse deposit of mucin composed primarily of hyaluronic acid in the upper and mid-reticular dermis; the presence of mucin can be confirmed with an Alcian blue stain (pH 2.5) or a colloidal iron stain and hyaluronidase digestion  (<a class="graphic graphic_picture graphicRef91125" href="/z/d/graphic/91125.html" rel="external">picture 6</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increase in collagen deposition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A marked proliferation of irregularly arranged fibroblasts.</p><p></p><p>The epidermis may be normal or thinned by the presence of the underlying mucin and fibrosis; the hair follicles may be atrophic, and a slight perivascular, superficial, lymphoplasmacytic infiltrate is often present. Sweat gland proliferations are found occasionally [<a href="#rid45">45</a>]. The elastic fibers are fragmented and decreased in number, explaining the clinical presentation of redundant skin folds on a sclerodermoid background [<a href="#rid46">46</a>]. </p><p>An interstitial, granuloma annulare-like pattern has been described in cutaneous biopsy specimens from patients with scleromyxedema, occurring in approximately 25 percent of the specimens [<a href="#rid47">47,48</a>]. This histologic pattern is characterized by a diffuse, interstitial proliferation of blue-gray histiocytes (CD68+, CD163+), giant cells, and lymphocytes within the papillary and mid-reticular dermis forming loose granulomas among collagen fibers and mucin deposits.</p><p>Histologic specimens from extracutaneous sites may demonstrate mucin deposition among myocardial cells and in the walls of myocardial blood vessels as well as in the interstitium of the kidney, lungs, pancreas, adrenal glands, and nerves [<a href="#rid26">26,34</a>]. Lymph node involvement with infiltration by numerous fibroblasts surrounded by mucin and collagen deposits has been observed [<a href="#rid49">49</a>]. Mucin has not been found in brain autopsies of patients who died of dermato-neuro syndrome.</p><p class="headingAnchor" id="H256448316"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of scleromyxedema is based upon the recognition of the following clinicopathologic criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>Generalized, papular and sclerodermoid eruption</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Microscopic triad, including mucin deposition, fibrosis, and fibroblast proliferation, or, less frequently, an interstitial granulomatous-like pattern</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal gammopathy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of thyroid disorder </p><p></p><p>Atypical forms of scleromyxedema include scleromyxedema in the absence of monoclonal gammopathy or scleromyxedema demonstrating an interstitial granulomatous-like pattern on histopathology. (See <a class="local">'Associated disorders'</a> above and <a class="local">'Histopathology'</a> above.)</p><p class="headingAnchor" id="H105606923"><span class="h2">Patient history</span><span class="headingEndMark"> — </span>The patient history is useful for identifying symptoms suggestive of extracutaneous involvement and functional limitations secondary to the disease. Patients should be asked about arthralgia, paresthesia, pain, and numbness of the hands (suggestive of associated carpal tunnel syndrome), weakness (suggestive of muscular involvement), dysphagia (suggestive of associated esophageal dysmotility), and dyspnea on exertion (suggestive of pulmonary involvement).</p><p class="headingAnchor" id="H105606930"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>A full skin examination should be performed in patients with suspected scleromyxedema to determine the extent of skin involvement and to identify signs that support the diagnosis or suggest a different disease. Findings of a widespread, papular eruption accompanied by skin induration (particularly involving the hands, face, or around the mouth) and edematous fingers and hands should raise suspicion for the diagnosis. </p><p>There is not a standardized method for grading the severity of cutaneous involvement in scleromyxedema. We have found the modified Rodnan skin score, a scoring system often used to assess the severity of skin involvement in systemic sclerosis (scleroderma), useful for following and documenting the severity of disease [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/7544.html" rel="external">"Pretreatment evaluation of adults with systemic sclerosis (scleroderma)", section on 'Skin involvement'</a>.)</p><p class="headingAnchor" id="H256448323"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>Skin biopsy is the mainstay for diagnosis and should be performed on a group of papules with underlying thickening. A 4 or 5 mm punch biopsy is sufficient for diagnosis. Key findings include mucin deposition, fibrosis, and fibroblast proliferation. (See  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Punch biopsy'</a> and <a class="local">'Histopathology'</a> above.)</p><p>Immunofluorescence studies are not contributory to the diagnosis of scleromyxedema and are usually negative [<a href="#rid51">51</a>]. Anecdotally, scanty granular IgG along the epidermal basement membrane and IgG and C1q focally along the connective tissue fibers in the dermis of clinically involved skin have been detected [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H27631351"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>The workup of patients with suspected scleromyxedema should include the following laboratory studies to determine whether the diagnostic criteria are met:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum protein immunoelectrophoresis and immunofixation and serum free light chain assay to evaluate for monoclonal gammopathy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid studies to rule out myxedema of thyroid disease (see  <a class="medical medical_review" href="/z/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function"</a>)</p><p></p><p>Serum protein immunofixation generally reveals the presence of a monoclonal protein, most commonly IgG-lambda type [<a href="#rid1">1</a>]. Thyroid function test results are normal. </p><p>We routinely obtain additional laboratory studies to evaluate for signs of systemic disease, including a complete blood count, comprehensive metabolic panel, muscle enzymes, and urinalysis. </p><p class="headingAnchor" id="H27631357"><span class="h2">Additional tests</span><span class="headingEndMark"> — </span>There is little value in imaging studies for the diagnosis of scleromyxedema, although high-resolution cutaneous ultrasonography may become a useful diagnostic and disease activity monitoring tool for skin thickening. </p><p>Dermoscopy is nonspecific, showing rice grain-like structures corresponding to papules. Reflectance confocal microscopy features include dermal stellate cells, bright fibers, and dark areas, corresponding to the classical triad of fibroblast proliferation, increased collagen deposition, and mucin deposits, respectively [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/13521.html" rel="external">"Overview of dermoscopy"</a>.)</p><p>Although not necessary for diagnosis, nail fold videocapillaroscopy is normal or nonspecific in scleromyxedema [<a href="#rid54">54</a>]. This differs from scleroderma, in which megacapillaries and decreased capillary density are characteristic features. </p><p>In patients who exhibit symptoms suggestive of extracutaneous disease, the corresponding internal organs should be evaluated. As examples, esophageal manometry can be useful for evaluating patients with dysphagia, and pulmonary function studies, including spirometry for forced vital capacity and quantification of diffusing capacity for carbon monoxide, are appropriate for patients with dyspnea. In dermato-neuro syndrome, lumbar puncture and magnetic resonance imaging typically reveal normal findings; however, electroencephalogram results may be consistent with toxic or metabolic encephalopathy [<a href="#rid16">16</a>]. (See <a class="local">'Extracutaneous manifestations'</a> above.)</p><p class="headingAnchor" id="H256448345"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The major disorders in the differential diagnosis of scleromyxedema are scleroderma (systemic sclerosis), scleredema, and nephrogenic systemic fibrosis [<a href="#rid55">55</a>]. Other disorders characterized by sclerodermoid skin changes may also enter the differential diagnosis  (<a class="graphic graphic_table graphicRef131273" href="/z/d/graphic/131273.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Causes of scleroderma-like skin changes'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic sclerosis </strong>– Characteristic cutaneous findings of systemic sclerosis include skin thickening or hardening that begins on the fingers, hands, or face with centripetal extension in the absence of papules. Raynaud phenomenon is present in more than 90 percent of patients and antecedes the sclerosis of fingers. Associated cutaneous findings include telangiectasia, digital ischemic ulcers, and calcinosis. Nailfold capillaroscopy is useful for early diagnosis of systemic sclerosis, showing dilated and giant capillaries, hemorrhages, disorganized vascular arrays, ramified/bushy capillaries, and capillary losses. Systemic scleroderma is associated with specific autoantibody profiles, including anti-Scl70 or anticentromere antibody. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Cutaneous manifestations'</a>.)</p><p></p><p class="bulletIndent1">Although patients with scleromyxedema may have symptoms that mimic scleroderma, such as sclerodactyly, the Raynaud phenomenon (rarely), and esophageal dysmotility, clinical and laboratory features distinguish the two diseases. The presence of diffuse, waxy papules in linear arrays and in a characteristic distribution that includes the glabella and posterior auricular area, the involvement of the middle portion of the back (always spared in scleroderma), and the presence of an IgG monoclonal gammopathy all favor a diagnosis of scleromyxedema. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scleredema </strong>–<strong> </strong>Scleredema (also known as scleredema adultorum of Buschke) is characterized by a symmetrical, nonpitting induration of the skin that typically begins on the neck and later spreads to the shoulders and upper part of the trunk with occasional erythema  (<a class="graphic graphic_picture graphicRef90965" href="/z/d/graphic/90965.html" rel="external">picture 7</a>). Scleredema is typically associated with a history of an antecedent upper respiratory infection, diabetes mellitus, or blood dyscrasia [<a href="#rid2">2</a>]. The histologic findings of scleromyxedema and scleredema differ; the fibroblast proliferation that is evident in histologic specimens of scleromyxedema is absent in scleredema [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/89274.html" rel="external">"Scleredema"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrogenic systemic fibrosis </strong>–<strong> </strong>Nephrogenic systemic fibrosis, which develops in individuals with renal dysfunction and exposure to gadolinium, can have a similar histologic appearance to scleromyxedema, with findings of mucin and fibroblastic proliferation in biopsy specimens. Common cutaneous findings of this condition include bilateral, symmetric, fibrotic, indurated papules, plaques, or subcutaneous nodules that begin on the distal extremities prior to progressing proximally  (<a class="graphic graphic_picture graphicRef69935" href="/z/d/graphic/69935.html" rel="external">picture 8</a>). Patients may also develop muscle, joint, internal organ, or scleral involvement.</p><p></p><p class="bulletIndent1">Clinical correlation is useful for distinguishing the two diseases. Unlike scleromyxedema, facial involvement (common in scleromyxedema), the presence of widespread papules, and monoclonal gammopathy are not features of nephrogenic systemic fibrosis. Scleral plaques have not been reported in scleromyxedema. (See  <a class="medical medical_review" href="/z/d/html/1955.html" rel="external">"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease"</a>.)</p><p></p><p>Importantly, scleromyxedema should be differentiated from the localized variants of lichen myxedematosus. In the past, the terms "papular mucinosis," "lichen myxedematosus," and "scleromyxedema" were often used indiscriminately. Although scleromyxedema and the localized type of lichen myxedematosus (including subtypes such as acral persistent papular mucinosis, discrete lichen myxedematosus, papular mucinosis of infancy, and nodular lichen myxedematosus) belong to the same disease spectrum, it is important to make a distinction between the two disorders because of differences in prognosis and the approach to therapy [<a href="#rid2">2,3</a>]. Historically, most patients reported in the literature to have lichen myxedematosus or papular mucinosis without specification of the disease subtype appear to have had scleromyxedema with monoclonal gammopathy. Occasionally, patients have overlapping or atypical features and fall in between scleromyxedema and localized lichen myxedematosus [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/110154.html" rel="external">"Localized lichen myxedematosus"</a>.) </p><p class="headingAnchor" id="H27631369"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Although treatment of scleromyxedema is recommended to minimize risk for the development of complications, a paucity of high-quality studies on the efficacy of treatments for scleromyxedema and an incomplete understanding of the pathogenesis of the disorder have prevented the development of definitive guidelines on the best approach to treatment. No randomized trials have evaluated therapies for scleromyxedema, and data are primarily limited to case reports and case series due to the rarity of the disease. No specific treatment appears to be uniformly effective or curative, and the relative efficacies of the treatments that have been utilized remain unclear. </p><p>As a consequence of the limited data on therapies for scleromyxedema, opinions vary on the preferred approach to treatment. In all cases, consideration of the risk-benefit ratio of treatment is important for selecting an appropriate therapeutic regimen; both scleromyxedema and its therapies may induce life-threatening side effects. </p><p>Complete resolution of the manifestations of scleromyxedema is the goal of treatment but is not always feasible. Marked improvement in papules and skin thickening is generally considered a successful response for skin disease [<a href="#rid50">50</a>]. Our typical approach to the treatment of scleromyxedema will be reviewed here. Consideration of patient characteristics, patient preferences, clinician experience, and treatment accessibility may support other approaches to treatment. Of note, successful treatment of scleromyxedema does not appear to require the resolution of the associated paraproteinemia. </p><p class="headingAnchor" id="H774293260"><span class="h2">Preferred initial therapy</span><span class="headingEndMark"> — </span>Systemic therapy is the treatment method of choice for patients with scleromyxedema. Intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>) is our first choice for therapy based upon multiple case reports and case series that support its efficacy and the generally well-tolerated nature of this nonimmunosuppressive treatment [<a href="#rid5">5,50,57</a>]. For those patients who cannot receive IVIG, systemic glucocorticoids and immunomodulatory drugs (<a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> or <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>) are our preferred initial systemic therapies. (See <a class="local">'Failure of initial therapy'</a> below.)</p><p>In the past, <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>, a chemotherapeutic agent given with the intent to treat the associated plasma cell dyscrasia, was often considered first-line treatment for scleromyxedema. However, concerns regarding serious adverse effects, including hematologic malignancies and opportunistic infections, contributed to a desire for other less toxic first-line therapies for scleromyxedema. </p><p class="headingAnchor" id="H27631375"><span class="h3">Intravenous immunoglobulin (IVIG)</span><span class="headingEndMark"> — </span>The mechanism through which <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> improves scleromyxedema is unclear. Suggested mechanisms focus on the immunomodulatory effects of IVIG, including neutralization of circulating autoantibodies by anti-idiotype antibodies, functional blockade of fragment crystallizable receptors on macrophages, and inhibition of fibrosis via modulation of the production of cytokines and cytokine antagonists [<a href="#rid58">58,59</a>].</p><p class="headingAnchor" id="H3393828070"><span class="h4">Administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> is usually administered at the dose of 2 g/kg per month divided over two to four consecutive days per month according to the preparation and concentration of IVIG. Improvement in skin and extracutaneous symptoms, especially rheumatologic symptoms, often is evident after the first one or two cycles of IVIG [<a href="#rid1">1,60,61</a>]. In our experience, almost all patients exhibit at least partial improvement within four to six cycles. Patients with an unsatisfactory response to IVIG after six cycles are typically transitioned to other therapies. (See <a class="local">'Failure of initial therapy'</a> below.)</p><p>Lower doses of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> may also be effective. A patient with skin-limited disease who had failed to respond to systemic glucocorticoids, extracorporeal photophoresis, and interferon had a reduction in clinical findings within two cycles of IVIG given at a dose of 0.5 g/kg given over five days at four-week intervals [<a href="#rid60">60</a>]. </p><p>Although remissions persisting for a few months to three years after cessation of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> infusions have been reported, the response to IVIG is usually transient [<a href="#rid29">29,61,62</a>]. Maintenance IVIG cycles every six to eight weeks are generally required to maintain remission [<a href="#rid61">61</a>]. We typically administer IVIG over two to four days at a dose of 2 g/kg of IVIG every six weeks or 1.5 g/kg of IVIG every four weeks.</p><p>Drawbacks of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> treatment are its high cost and the time-consuming administration. The use of more concentrated IVIG, reducing the time of administration to two days, has improved the management of the disease. Possible side effects are skin flushes, hand dermatitis, arthralgias, myalgias, fever, headache, thoracic or abdominal pain, nausea, and tachycardia. Myocardial ischemia and death secondary to suspected myocardial infarction have been reported in scleromyxedema patients with known cardiac risk factors during treatment with IVIG [<a href="#rid1">1,63</a>]. However, the side effects experienced by patients receiving IVIG for scleromyxedema generally have been mild and self-limited [<a href="#rid64">64</a>]. The adverse effects of IVIG are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a>.)</p><p class="headingAnchor" id="H1949625"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Data on the efficacy and safety of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> are primarily limited to case reports and case series; no randomized trials have been performed [<a href="#rid1">1,5,6,29</a>]. Examples of published reports that have offered support for the efficacy of IVIG for this disease include:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study, 13 of 31 patients (42 percent) with scleromyxedema (without features of dermato-neuro syndrome or mucinous cardiac involvement) treated with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> (2 g/kg monthly for the first six months) as a first- or second-line therapy achieved a complete clinical response [<a href="#rid5">5</a>]. Patients were treated with IVIG for a median of 16 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a review of eight adults with scleromyxedema who were treated with monthly cycles of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> (2 g/kg per cycle divided over two to five days), two achieved a complete response and six achieved a partial response after up to six cycles of IVIG [<a href="#rid29">29</a>]. Treatment was followed by maintenance therapy every 6 to 12 weeks as needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter, retrospective study of 30 patients with scleromyxedema, three of the six patients treated with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> (2 g/kg per monthly cycle) achieved complete clinical remissions [<a href="#rid1">1</a>]. The three remaining patients achieved partial responses.</p><p></p><p>In the first study, a complete clinical response was defined as complete clinical improvement from baseline. In the latter two studies, complete responses were defined as an absence of systemic symptoms or skin findings of scleromyxedema, and partial responses consisted of a decrease in skin changes and improvement in systemic symptoms. In these and other reports, responders to <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> have included both patients who received IVIG as initial treatment and patients who had previously failed other therapies [<a href="#rid1">1,5,29,61,65</a>].</p><p class="headingAnchor" id="H1338860"><span class="h2">Failure of initial therapy</span><span class="headingEndMark"> — </span>When treatment with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> is not an option or yields an insufficient response, we institute other therapies. Systemic glucocorticoids and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> are our preferred next-line treatments. Systemic glucocorticoids and thalidomide can be given alone. More often, we add one of these agents to IVIG therapy because of the favorable results we have observed with combination therapy.</p><p>Selection between systemic glucocorticoids and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> is based upon consideration of factors such as patient comorbidities, tolerability, drug availability, and clinician comfort. Most often we use systemic glucocorticoids first; if the response is insufficient, we begin thalidomide.</p><p>Patients with severe disease who cannot be successfully managed with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and/or systemic glucocorticoids are candidates for trials of more aggressive interventions. (See <a class="local">'Severe and refractory disease'</a> below.)</p><p class="headingAnchor" id="H1077715615"><span class="h3">Systemic glucocorticoids</span><span class="headingEndMark"> — </span>Systemic glucocorticoids have been used for scleromyxedema as monotherapy or in conjunction with chemotherapeutic agents [<a href="#rid66">66,67</a>]. It is postulated that benefit from systemic glucocorticoids may result from immunosuppressive and antifibroblast effects of these agents [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H995992100"><span class="h4">Administration</span><span class="headingEndMark"> — </span>Our preferred regimen for systemic glucocorticoid therapy is <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (0.5 to 1 mg/kg per day) until the desired therapeutic effect is reached. Responses usually occur within four weeks. Then, we begin to slowly taper the glucocorticoid dose to the lowest dose necessary to maintain the response to treatment. If patients fail to respond within four to six weeks, we consider treatment ineffective and typically transition to <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>.</p><p>The adverse effects of systemic glucocorticoid therapy are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H2552954958"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Data on the efficacy of systemic glucocorticoids in scleromyxedema are limited to case reports. <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> (0.5 to 1 mg/kg per day), <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> (0.3 to 0.5 mg/kg per day), and oral high-dose <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (40 mg once daily for four days per week during three consecutive weeks each month) have been associated with improvement in cutaneous manifestations of scleromyxedema in individual patients [<a href="#rid68">68-70</a>]. The associated paraproteinemia may or may not improve in patients in whom systemic glucocorticoid therapy induces remission of scleromyxedema [<a href="#rid69">69,70</a>]. Failure of systemic glucocorticoid therapy to improve scleromyxedema has also been reported [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H27631381"><span class="h3">Immunomodulatory drugs (thalidomide or lenalidomide)</span><span class="headingEndMark"> — </span>The mechanism of action of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> in scleromyxedema is unknown. Immunomodulatory effects on proinflammatory and profibrotic cytokines and antiangiogenic properties may contribute to inhibition of fibrosis [<a href="#rid71">71</a>].</p><p><a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">Lenalidomide</a>, a <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> derivative with a more favorable side effect profile, may be a reasonable alternative to thalidomide. Disadvantages of lenalidomide compared with thalidomide include higher cost and less data on the efficacy of this therapy.</p><p class="headingAnchor" id="H3733941108"><span class="h4">Administration</span><span class="headingEndMark"> — </span>Treatment with <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> should begin at a dose of 50 to 100 mg per day. The dose is slowly increased according to clinical response and tolerance up to 150 to 400 mg per day. Clinical improvement is expected within two to three months, and a change in therapy is appropriate for patients who do not exhibit improvement within this period. (See <a class="local">'Severe and refractory disease'</a> below.)</p><p>Once a satisfactory response to <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> is achieved, the lowest dose effective for maintaining improvement is used for maintenance therapy.</p><p>Teratogenicity and peripheral neuropathy are side effects of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> that can limit the use of this therapy. Patients should be monitored for the development of peripheral neuropathy during treatment. In the United States, patient and provider participation in a Risk Evaluation and Mitigation Strategy program (www.thalomidrems.com), a program aimed to prevent the use of thalidomide during pregnancy, is required for the use of this medication. Other potential adverse effects of thalidomide include drowsiness, constipation, thrombosis, and leukopenia.</p><p><a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">Lenalidomide</a> is usually used at a dose of 10 to 25 mg per day for three weeks per month, starting with the lower dose. Once response is achieved, the lenalidomide dose can be reduced to the lowest dose effective for maintaining improvement.</p><p>Examples of potential adverse effects of <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> include teratogenicity, thrombocytopenia, neutropenia, and thrombosis. In the United States, lenalidomide is available under a restricted distribution program (Revlimid REMS). Peripheral neuropathy, sedation, and constipation occur to a lesser extent with lenalidomide compared with <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>. </p><p class="headingAnchor" id="H2312057875"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Multiple case reports have documented improvement in the cutaneous manifestations of scleromyxedema following treatment with <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> [<a href="#rid72">72-77</a>]. Improvement in systemic manifestations [<a href="#rid77">77</a>] and serum paraprotein levels [<a href="#rid72">72</a>] have also been reported in some patients. Thalidomide may be a useful adjunct to <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> therapy; the addition of thalidomide to IVIG appeared to be useful for decreasing the frequency of IVIG treatment in a case report [<a href="#rid71">71</a>].</p><p>A few case reports and series have documented the use of <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>. In a retrospective study, treatment of three patients with IVIG-refractory scleromyxedema with lenalidomide, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, and <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> was associated with partial clinical responses and complete hematologic responses in all patients [<a href="#rid5">5</a>]. In case reports, lenalidomide (25 mg per day for three weeks per month) appeared beneficial when used in combination with IVIG in one patient [<a href="#rid78">78</a>] but failed to induce clinical improvement when used in combination with dexamethasone in another patient [<a href="#rid13">13</a>]. </p><p class="headingAnchor" id="H188062601"><span class="h2">Severe and refractory disease</span><span class="headingEndMark"> — </span>Patients who fail to achieve sufficient improvement with the therapies above may benefit from interventions aimed at treating the associated plasma cell dyscrasia. </p><p>Examples of therapeutic options we typically reserve for these patients include <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, autologous stem cell transplantation, and <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>. Data are limited on the efficacy of these therapies for cutaneous and extracutaneous manifestations of scleromyxedema. In addition, the response to these treatments is variable and relapse may occur. Thus, the risks associated with these therapies must be considered carefully prior to treatment. </p><p>Our typical approach to severe disease that has failed to respond to <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, systemic glucocorticoids, and immunomodulatory drugs starts with <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> therapy. Poor responders are candidates for autologous stem cell transplantation. We generally avoid <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> because of concern for serious hematologic toxicity, including malignancy (see  <a class="drug drug_general" href="/z/d/drug information/9605.html" rel="external">"Melphalan: Drug information"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bortezomib</strong><strong> and </strong><strong>dexamethasone</strong><strong> </strong>– Combination therapy with <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> has been associated with rapid improvement in cutaneous manifestations and constitutional symptoms of scleromyxedema in case reports, including a patient who relapsed after autologous stem cell transplantation [<a href="#rid13">13,79</a>]. A successful response was also observed in a patient treated with bortezomib and dexamethasone in combination with <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">Our typical regimen involves <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> given at a dose of 1.3 mg/m<sup>2</sup> (maximum of 2 mg per dose) on days 1, 8, 15, and 22. <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">Dexamethasone</a> (40 mg per dose) is given on days 1, 8, 15, and 22. A total of six cycles are given over a period of six months. In very refractory cases, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> may be added, given at a dose of 100 mg per day for the first 14 days followed by 200 mg per day for the next seven days, similar to a protocol used for myeloma. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous stem cell transplantation </strong>– Multiple cases of scleromyxedema treated with autologous stem cell transplantation have been reported since the initial report of a complete remission in 2001 [<a href="#rid8">8</a>]. In a review of 17 reported cases of scleromyxedema treated with autologous stem cell transplantation published between 2001 and 2011, complete remissions (resolution of all clinical symptoms, skin abnormality, and serum paraprotein) were attained by 10 patients (59 percent) and partial remissions were attained by 5 patients (29 percent) [<a href="#rid80">80</a>]. However, only two of the complete responders remained in remission after follow-up periods ranging between 14 and &gt;60 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melphalan</strong><strong> </strong>– Although <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> was often considered a first-line treatment for scleromyxedema in the past, the potential for drug-related serious adverse events limits the use of this agent. A review of 17 patients who received melphalan for scleromyxedema (1 to 4 mg per day or cyclic therapy) at a single medical center found that although 12 patients had improvement of skin disease with therapy, improvement was temporary in 8 patients and 9 patients died of hematologic malignancy or septic complications that were considered related to therapy [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H2401552658"><span class="h2">Dermato-neuro syndrome</span><span class="headingEndMark"> — </span>The approach to patients with dermato-neuro syndrome is not standardized, and various treatments have seemed to yield benefit in case reports. Examples include <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> [<a href="#rid65">65</a>], systemic glucocorticoids plus plasmapheresis or IVIG [<a href="#rid18">18,81</a>], systemic glucocorticoids plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and plasmapheresis [<a href="#rid5">5,15</a>], <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> plus IVIG, and <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid82">82</a>]. Spontaneous improvement also has been reported [<a href="#rid16">16</a>]. </p><p>Our typical initial approach consists of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> (2 g per kg per month) with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> pulse therapy (intravenous dexamethasone [100 mg per day] given for three consecutive days per month). This may be followed by the addition of plasmapheresis (every other day for 10 days) for patients who do not improve within two cycles of IVIG and dexamethasone therapy. </p><p class="headingAnchor" id="H105606563"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Case reports have documented clinical improvement in patients treated with topical <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> and topical <a class="drug drug_general" data-topicid="8898" href="/z/d/drug information/8898.html" rel="external">dimethyl sulfoxide</a> [<a href="#rid83">83</a>], topical and intralesional corticosteroid therapy [<a href="#rid84">84</a>], oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid85">85,86</a>], <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> [<a href="#rid1">1</a>], interferon-alfa [<a href="#rid87">87</a>], <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> [<a href="#rid1">1</a>], <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid88">88</a>], and chemotherapeutic agents, including <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid89">89</a>], <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid21">21,90</a>], <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> [<a href="#rid91">91</a>], and 2-chlorodesoxyadenosine [<a href="#rid92">92</a>]. The efficacies of these agents for scleromyxedema remain to be confirmed. Of note, treatment with interferon-alfa was associated with worsening of symptoms in a woman with localized lichen myxedematosus [<a href="#rid93">93</a>]. </p><p>Ultraviolet A1 (UVA1) or psoralen plus ultraviolet A (PUVA) phototherapy [<a href="#rid94">94</a>], Grenz ray [<a href="#rid33">33,95</a>], and total skin electron beam therapy [<a href="#rid96">96</a>] have also been reported to improve cutaneous manifestations of scleromyxedema in case reports. These therapies do not have an impact on paraproteinemia and systemic involvement. Of note, accidental excessive exposure to ultraviolet B (UVB) has appeared to exacerbate the disease in one patient [<a href="#rid97">97</a>]. Allogeneic hematopoietic cell transplant has also been tried with success in a patient with refractory disease [<a href="#rid98">98</a>]. </p><p>Tumor necrosis factor (TNF)-alpha inhibitors may not be useful. TNF-alpha has been suggested as a profibrotic cytokine that may be implicated in the pathogenesis of scleromyxedema, and a patient in whom <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> lost efficacy failed to respond to <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H105606619"><span class="h2">Cosmetic interventions</span><span class="headingEndMark"> — </span>Case reports suggest that facial disfigurement can be treated with dermabrasion plus surgery or carbon dioxide laser with good cosmetic results [<a href="#rid100">100,101</a>]. These procedures do not affect systemic manifestations of scleromyxedema.</p><p class="headingAnchor" id="H193081404"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Scleromyxedema is a disease with an unpredictable but usually progressive and disabling course in the absence of successful treatment. Even when therapy is successful, long-term maintenance therapy usually is required since relapse commonly occurs upon the discontinuation of treatment. Death may result from complications of extracutaneous involvement or adverse effects of therapy. (See <a class="local">'Clinical course'</a> above.)</p><p>Because of the various cutaneous and extracutaneous manifestations of scleromyxedema, a multispecialty team often is needed for the optimal management of these patients. Depending on the manifestations present, dermatologists, hematologists, cardiologists, pulmonologists, gastroenterologists, hand surgeons, and other specialists can be valuable for managing affected patients. </p><p>The unpredictable course of scleromyxedema, the variable response to treatment, and the common occurrence of relapse demand close, long-term follow-up of these patients. We usually reassess patients once per month with a full skin examination, review of systems, and reevaluation of the therapeutic regimen. Serologic studies, including assessment of the status of the associated monoclonal gammopathy, are not useful for monitoring disease activity.</p><p>Patients should be cautioned that development of neurologic symptoms (eg, dysarthria) and flu-like illness may be the initial signs of dermato-neuro syndrome. Patients with such symptoms should be admitted to the hospital for close observation, evaluation, and eventually admission to the intensive care unit.</p><p>Follow-up data on patients treated for scleromyxedema are limited, but relapse after treatment appears to be common. Most patients treated with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> require continued therapy to remain in remission [<a href="#rid29">29,61</a>]. Frequent relapses have also been reported following autologous bone marrow transplantation and <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> therapy [<a href="#rid28">28,80</a>]. No treatment has been identified that definitively cures the disease. </p><p class="headingAnchor" id="H1196968317"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/131811.html" rel="external">"Society guideline links: Scleromyxedema and localized lichen myxedematosus"</a>.)</p><p class="headingAnchor" id="H193081465"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Scleromyxedema is an uncommon, diffuse/generalized, papular and cutaneous eruption that usually occurs in association with monoclonal gammopathy and may have accompanying systemic features. The disorder typically affects adults. There is no sex predilection. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– The pathogenesis of scleromyxedema is unknown, but circulating cytokines, such as interleukin (IL) 1, tumor necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta, and IL-4, known to stimulate glycosaminoglycan synthesis and fibroblast proliferation in the skin, seem to play a role. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Pathogenesis'</a> above and <a class="local">'Associated disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical findings </strong>– The cutaneous manifestations of scleromyxedema consist of widespread, waxy papules and indurated plaques  (<a class="graphic graphic_picture graphicRef91117 graphicRef91118 graphicRef91121" href="/z/d/graphic/91117.html" rel="external">picture 1A-C</a>). Progressive cutaneous involvement can lead to decreased motility of the mouth and joints. Extracutaneous involvement in scleromyxedema can present with a variety of manifestations. Neurologic, musculoskeletal, cardiac, gastrointestinal, respiratory, or renal abnormalities may develop. (See <a class="local">'Clinical findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course </strong>– The clinical course of scleromyxedema is chronic and progressive. Cutaneous and extracutaneous involvement can lead to significant morbidity. Death may result from complications related to extracutaneous involvement, such as dermato-neuro syndrome, or adverse effects of therapy. (See <a class="local">'Clinical course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of scleromyxedema is based upon recognition of consistent clinical, pathologic, and laboratory findings. The presence of the following features is supportive of the diagnosis (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse/generalized, papular and sclerodermoid eruption</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Microscopic triad, including mucin deposition, fibrosis, and fibroblast proliferation, or, less frequently, an interstitial granulomatous-like pattern</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monoclonal gammopathy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absence of thyroid disorder</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– There is a paucity of data on the treatment options for scleromyxedema. The available data consist primarily of case reports and case series. Thus, there are no definitive guidelines on the best approach to treatment (see <a class="local">'Treatment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment </strong>– Patients with scleromyxedema generally require systemic therapy. We suggest intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>) as initial treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Systemic glucocorticoids and immunomodulatory drugs (<a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> or <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>) are alternative treatment options that may also be used in conjunction with IVIG therapy. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe and refractory disease </strong>– Patients who fail to respond to <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, systemic glucocorticoids, or immunomodulatory drugs may benefit from other therapies. Examples of treatment options for severe and refractory disease include <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, autologous stem cell transplantation, and <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>. The risk-benefit ratios of treatment must be carefully considered prior to therapy. (See <a class="local">'Severe and refractory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– Recurrence of scleromyxedema is common after withdrawal of an effective therapy. Long-term maintenance treatment usually is required, and close clinical follow-up is necessary. (See <a class="local">'Prognosis and follow-up'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 2013; 69:66.</a></li><li class="breakAll">Rongioletti F, Rebora A. Mucinoses. In: Dermatology, 3rd ed, Bolognia J, Jorizzo JL, Schaffer JV, et al (Eds), Elsevier, 2012. Vol 1, p.687.</li><li><a class="nounderline abstract_t">Rongioletti F. Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg 2006; 25:100.</a></li><li><a class="nounderline abstract_t">Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol 2006; 24:493.</a></li><li><a class="nounderline abstract_t">Mahévas T, Arnulf B, Bouaziz JD, et al. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. Blood 2020; 135:1101.</a></li><li><a class="nounderline abstract_t">Mecoli CA, Talbot CC Jr, Fava A, et al. Clinical and Molecular Phenotyping in Scleromyxedema Pretreatment and Posttreatment With Intravenous Immunoglobulin. Arthritis Care Res (Hoboken) 2020; 72:761.</a></li><li><a class="nounderline abstract_t">Kalli F, Cioni M, Parodi A, et al. Increased frequency of interleukin-4 and reduced frequency of interferon-γ and IL-17-producing CD4+ and CD8+ cells in scleromyxedema. J Eur Acad Dermatol Venereol 2020; 34:1092.</a></li><li><a class="nounderline abstract_t">Feasel AM, Donato ML, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol 2001; 137:1071.</a></li><li><a class="nounderline abstract_t">Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 1978; 199:545.</a></li><li><a class="nounderline abstract_t">Ferrarini M, Helfrich DJ, Walker ER, et al. Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol 1989; 16:837.</a></li><li><a class="nounderline abstract_t">Yaron M, Yaron I, Yust I, Brenner S. Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 1985; 12:171.</a></li><li><a class="nounderline abstract_t">Yeung CK, Loong F, Kwong YL. Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. Br J Haematol 2012; 157:411.</a></li><li><a class="nounderline abstract_t">Migkou M, Gkotzamanidou M, Terpos E, et al. Response to bortezomib of a patient with scleromyxedema refractory to other therapies. Leuk Res 2011; 35:e209.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Cattarini G, Sottofattori E, Rebora A. Granulomatous reaction after intradermal injections of hyaluronic acid gel. Arch Dermatol 2003; 139:815.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Hazini A, Rebora A. Coma associated with scleromyxoedema and interferon alfa therapy. Full recovery after steroids and cyclophosphamide combined with plasmapheresis. Br J Dermatol 2001; 144:1283.</a></li><li><a class="nounderline abstract_t">Fleming KE, Virmani D, Sutton E, et al. Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature. J Cutan Pathol 2012; 39:508.</a></li><li><a class="nounderline abstract_t">Berger JR, Dobbs MR, Terhune MH, Maragos WF. The neurologic complications of scleromyxedema. Medicine (Baltimore) 2001; 80:313.</a></li><li><a class="nounderline abstract_t">Rey JB, Luria RB. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol 2009; 60:1037.</a></li><li><a class="nounderline abstract_t">Espinosa A, De Miguel E, Morales C, et al. Scleromyxedema associated with arthritis and myopathy: a case report. Clin Exp Rheumatol 1993; 11:545.</a></li><li><a class="nounderline abstract_t">Jamieson TW, De Smet AA, Stechschulte DJ. Erosive arthropathy associated with scleromyxedema. Skeletal Radiol 1985; 14:286.</a></li><li><a class="nounderline abstract_t">Helfrich DJ, Walker ER, Martinez AJ, Medsger TA Jr. Scleromyxedema myopathy: case report and review of the literature. Arthritis Rheum 1988; 31:1437.</a></li><li><a class="nounderline abstract_t">Launay D, Hatron PY, Delaporte E, et al. Scleromyxedema (lichen myxedematosus) associated with dermatomyositis. Br J Dermatol 2001; 144:359.</a></li><li><a class="nounderline abstract_t">Rothe MJ, Rivas R, Gould E, Kerdel FA. Scleromyxedema and severe myositis. Int J Dermatol 1989; 28:657.</a></li><li><a class="nounderline abstract_t">Ozdag F, Akar A, Eroglu E, Erbil H. Acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa. J Dermatolog Treat 2001; 12:167.</a></li><li><a class="nounderline abstract_t">Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol 2003; 42:31.</a></li><li><a class="nounderline abstract_t">De Simone C, Castriota M, Carbone A, et al. Cardiomyopathy in scleromyxedema: report of a fatal case. Eur J Dermatol 2010; 20:852.</a></li><li><a class="nounderline abstract_t">Morris-Jones R, Staughton RC, Walker M, et al. Lichen myxoedematosus with associated cardiac abnormalities. Br J Dermatol 2001; 144:594.</a></li><li><a class="nounderline abstract_t">Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol 1995; 33:37.</a></li><li><a class="nounderline abstract_t">Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore) 2008; 87:10.</a></li><li><a class="nounderline abstract_t">Le Moigne M, Mazereeuw-Hautier J, Bonnetblanc JM, et al. [Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study]. Ann Dermatol Venereol 2010; 137:782.</a></li><li><a class="nounderline abstract_t">Rapp MF, Guram M, Konrad HR, et al. Laryngeal involvement in scleromyxedema: a case report. Otolaryngol Head Neck Surg 1991; 104:362.</a></li><li><a class="nounderline abstract_t">Lee YH, Sahu J, O'Brien MS, et al. Scleroderma renal crisis-like acute renal failure associated with mucopolysaccharide accumulation in renal vessels in a patient with scleromyxedema. J Clin Rheumatol 2011; 17:318.</a></li><li><a class="nounderline abstract_t">Godby A, Bergstresser PR, Chaker B, Pandya AG. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol 1998; 38:289.</a></li><li><a class="nounderline abstract_t">Loggini B, Pingitore R, Avvenente A, et al. Lichen myxedematosus with systemic involvement: clinical and autopsy findings. J Am Acad Dermatol 2001; 45:606.</a></li><li><a class="nounderline abstract_t">Gonzalez J, Palangio M, Schwartz J, et al. Scleromyxedema with dermato-neuro syndrome. J Am Acad Dermatol 2000; 42:927.</a></li><li><a class="nounderline abstract_t">Fritz M, Tinker D, Wessel AW, et al. SARS-CoV-2: A potential trigger of dermato-neuro syndrome in a patient with scleromyxedema. JAAD Case Rep 2021; 18:99.</a></li><li><a class="nounderline abstract_t">Bhoyrul B, Mughal AA, Paulus J, et al. Does dermatoneuro syndrome have a viral aetiology? Clin Exp Dermatol 2016; 41:53.</a></li><li><a class="nounderline abstract_t">Anguelova GV, Jellema K, Wagemakers S, Peters R. Two patients with dermatoneuro syndrome after influenza A infection. Eur J Neurol 2021; 28:e65.</a></li><li><a class="nounderline abstract_t">Chan JC, Trendell-Smith NJ, Yeung CK. Scleromyxedema: a cutaneous paraneoplastic syndrome associated with thymic carcinoma. J Clin Oncol 2012; 30:e27.</a></li><li><a class="nounderline abstract_t">Alfadley A, Al Hoqail I, Al Eisa A. Scleromyxedema: possible association with seminoma. J Am Acad Dermatol 2000; 42:875.</a></li><li><a class="nounderline abstract_t">Oh SJ, Oh SH, Jun JY, et al. Paraneoplastic atypical scleromyxedema with advanced gastric cancer. JAAD Case Rep 2017; 3:376.</a></li><li><a class="nounderline abstract_t">Hardie RA, Hunter JA, Urbaniak S, Habeshaw JA. Spontaneous resolution of lichen myxoedematosus. Br J Dermatol 1979; 100:727.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Rebora A. Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol 2001; 23:257.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44:273.</a></li><li><a class="nounderline abstract_t">Stücker M, Nowack U, Röchling A, et al. Sweat gland proliferations in scleromyxedema. Am J Dermatopathol 1999; 21:259.</a></li><li><a class="nounderline abstract_t">Gonzalez Santiago TM, Lehman JS, Buonaccorsi JN, et al. Frequency of cutis laxa-like clinical features and elastolysis in scleromyxedema: a retrospective clinicopathologic study of 19 patients with scleromyxedema. J Cutan Pathol 2016; 43:246.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Cozzani E, Parodi A. Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare. J Cutan Pathol 2010; 37:1084.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Merlo G, Carli C, et al. Histopathologic characteristics of scleromyxedema: A study of a series of 34 cases. J Am Acad Dermatol 2016; 74:1194.</a></li><li><a class="nounderline abstract_t">Delyon J, Bézier M, Rybojad M, et al. Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy. Virchows Arch 2013; 462:679.</a></li><li><a class="nounderline abstract_t">Guarneri A, Cioni M, Rongioletti F. High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatol Venereol 2017; 31:1157.</a></li><li><a class="nounderline abstract_t">Farmer ER, Hambrick GW Jr, Shulman LE. Papular mucinosis. A clinicopathologic study of four patients. Arch Dermatol 1982; 118:9.</a></li><li><a class="nounderline abstract_t">Krajnc I, Vizjak A, Hvala A, et al. [Significance of histopathologic analysis of skin lesions in scleromyxedema. Light microscopy, electron microscopy, immunohistochemistry and immunofluorescence microscopy]. Acta Med Austriaca 1998; 25:109.</a></li><li><a class="nounderline abstract_t">Mendes Bastos P, Borges AS, Cardoso JC, Oliveira A. Dermoscopy and reflectance confocal microscopy for the diagnosis of scleromyxedema. JAAD Case Rep 2019; 5:451.</a></li><li><a class="nounderline abstract_t">Serra S, Ambrósio C, João Salvador M, et al. [A cutaneous thickening case...]. Acta Reumatol Port 2010; 35:66.</a></li><li><a class="nounderline abstract_t">Ferreli C, Gasparini G, Parodi A, et al. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol 2017; 53:306.</a></li><li class="breakAll">Weedon D. Cutaneous mucinoses. In: Weedon's Skin Pathology, 3rd ed., Elsevier Limited, 2010. p.353.</li><li><a class="nounderline abstract_t">Knobler R, Moinzadeh P, Hunzelmann N, et al. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol 2017; 31:1581.</a></li><li><a class="nounderline abstract_t">Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484.</a></li><li><a class="nounderline abstract_t">Molina V, Blank M, Shoenfeld Y. Intravenous immunoglobulin and fibrosis. Clin Rev Allergy Immunol 2005; 29:321.</a></li><li><a class="nounderline abstract_t">Körber A, Franckson T, Grabbe S, Dissemond J. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin. J Eur Acad Dermatol Venereol 2007; 21:553.</a></li><li><a class="nounderline abstract_t">Bidier M, Zschoche C, Gholam P, et al. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol 2012; 92:408.</a></li><li><a class="nounderline abstract_t">Righi A, Schiavon F, Jablonska S, et al. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis 2002; 61:59.</a></li><li><a class="nounderline abstract_t">Binitha MP, Nandakumar G, Thomas D. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema. Indian J Dermatol Venereol Leprol 2008; 74:248.</a></li><li><a class="nounderline abstract_t">Sroa N, Campbell S, Bechtel M. Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature. J Drugs Dermatol 2010; 9:263.</a></li><li><a class="nounderline abstract_t">Gholam P, Hartmann M, Enk A. Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins. Br J Dermatol 2007; 157:1058.</a></li><li><a class="nounderline abstract_t">Wright RC, Franco RS, Denton D, Blaney DJ. Scleromyxedema. Arch Dermatol 1976; 112:63.</a></li><li><a class="nounderline abstract_t">Rayson D, Lust JA, Duncan A, Su WP. Scleromyxedema: a complete response to prednisone. Mayo Clin Proc 1999; 74:481.</a></li><li><a class="nounderline abstract_t">Lin YC, Wang HC, Shen JL. Scleromyxedema: An experience using treatment with systemic corticosteroid and review of the published work. J Dermatol 2006; 33:207.</a></li><li><a class="nounderline abstract_t">Kreuter A, Altmeyer P. High-dose dexamethasone in scleromyxedema: report of 2 additional cases. J Am Acad Dermatol 2005; 53:739.</a></li><li><a class="nounderline abstract_t">Horn KB, Horn MA, Swan J, et al. A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol 2004; 51:S120.</a></li><li><a class="nounderline abstract_t">Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum 2008; 38:188.</a></li><li><a class="nounderline abstract_t">Sansbury JC, Cocuroccia B, Jorizzo JL, et al. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 2004; 51:126.</a></li><li><a class="nounderline abstract_t">Guarenti I, Sebastiani V, Pinto G, et al. Successful treatment of scleromyxedema with oral thalidomide. Int J Dermatol 2013; 52:631.</a></li><li><a class="nounderline abstract_t">Amini-Adle M, Thieulent N, Dalle S, et al. Scleromyxedema: successful treatment with thalidomide in two patients. Dermatology 2007; 214:58.</a></li><li><a class="nounderline abstract_t">Jacob SE, Fien S, Kerdel FA. Scleromyxedema, a positive effect with thalidomide. Dermatology 2006; 213:150.</a></li><li><a class="nounderline abstract_t">Martins A, Paiva Lopes MJ, Tavares Belo R, Rodrigues JC. Scleromyxedema--thalidomide therapy. J Eur Acad Dermatol Venereol 2008; 22:622.</a></li><li><a class="nounderline abstract_t">Thyssen JP, Zachariae C, Menné T. Successful treatment of scleromyxedema using thalidomide. J Eur Acad Dermatol Venereol 2006; 20:1396.</a></li><li><a class="nounderline abstract_t">Brunet-Possenti F, Hermine O, Marinho E, et al. Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema. J Am Acad Dermatol 2013; 69:319.</a></li><li><a class="nounderline abstract_t">Cañueto J, Labrador J, Román C, et al. The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights. Eur J Haematol 2012; 88:450.</a></li><li><a class="nounderline abstract_t">Bos R, de Waal EG, Kuiper H, et al. Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. Rheumatology (Oxford) 2011; 50:1925.</a></li><li><a class="nounderline abstract_t">River Y, Levy I, Gilead L, et al. Fever, convulsions and coma in scleromyxedema: a "dermato-neuro syndrome". Neurology 1996; 46:1778.</a></li><li><a class="nounderline abstract_t">Fett NM, Toporcer MB, Dalmau J, et al. Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol 2011; 86:893.</a></li><li><a class="nounderline abstract_t">Bonnetblanc JM, Bedane C. Regression of scleromyxedema with topical betamethasone and dimethyl sulfoxide: a 30-month follow-up. Arch Dermatol 1991; 127:1733.</a></li><li><a class="nounderline abstract_t">Reynolds NJ, Collins CM, Burton JL. Discrete papular mucinosis responding to intralesional and topical steroids. Arch Dermatol 1992; 128:857.</a></li><li><a class="nounderline abstract_t">Hisler BM, Savoy LB, Hashimoto K. Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol 1991; 24:854.</a></li><li><a class="nounderline abstract_t">Milam CP, Cohen LE, Fenske NA, Ling NS. Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol 1988; 19:469.</a></li><li><a class="nounderline abstract_t">Tschen JA, Chang JR. Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol 1999; 40:303.</a></li><li><a class="nounderline abstract_t">Saigoh S, Tashiro A, Fujita S, et al. Successful treatment of intractable scleromyxedema with cyclosporin A. Dermatology 2003; 207:410.</a></li><li><a class="nounderline abstract_t">Kuldeep CM, Mittal AK, Gupta LK, et al. Successful treatment of scleromyxedema with dexamethasone cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol 2005; 71:44.</a></li><li><a class="nounderline abstract_t">Mehta V, Balachandran C, Rao R. Arndt Gottron scleromyxedema: successful response to treatment with steroid minipulse and methotrexate. Indian J Dermatol 2009; 54:193.</a></li><li><a class="nounderline abstract_t">Schirren CG, Betke M, Eckert F, Przybilla B. [Arndt-Gottron scleromyxedema. Case report and review of therapeutic possibilities]. Hautarzt 1992; 43:152.</a></li><li><a class="nounderline abstract_t">Davis LS, Sanal S, Sangueza OP. Treatment of scleromyxedema with 2-chlorodeoxyadenosine. J Am Acad Dermatol 1996; 35:288.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Rebora A. Worsening of lichen myxedematosus during interferon alfa-2a therapy for chronic active hepatitis C. J Am Acad Dermatol 1998; 38:760.</a></li><li><a class="nounderline abstract_t">Brenner M, Herzinger T, Berking C, et al. Phototherapy and photochemotherapy of sclerosing skin diseases. Photodermatol Photoimmunol Photomed 2005; 21:157.</a></li><li><a class="nounderline abstract_t">Kantor GR, Bergfeld WF, Katzin WE, et al. Scleromyxedema associated with scleroderma renal disease and acute psychosis. J Am Acad Dermatol 1986; 14:879.</a></li><li><a class="nounderline abstract_t">Rampino M, Garibaldi E, Ragona R, Ricardi U. Scleromyxedema: treatment of widespread cutaneous involvement by total skin electron-beam therapy. Int J Dermatol 2007; 46:864.</a></li><li><a class="nounderline abstract_t">Yamazaki S, Fujisawa T, Yanatori A, Yamakage A. A case of lichen myxedematosus with clearly exacerbated skin eruptions after UVB irradiation. J Dermatol 1995; 22:590.</a></li><li><a class="nounderline abstract_t">Shayegi N, Alakel N, Middeke JM, et al. Allogeneic stem cell transplantation for the treatment of refractory scleromyxedema. Transl Res 2015; 165:321.</a></li><li><a class="nounderline abstract_t">Arginelli F, Paganelli A, Rongioletti F, et al. Ineffectiveness of infliximab CT-P13 for the treatment of scleromyxedema: A case report. Dermatol Ther 2018; 31:e12583.</a></li><li><a class="nounderline abstract_t">Acikel C, Karagoz H, Kucukodaci Z. Surgical treatment of facial disfigurement due to lichen myxedematosus. Dermatol Surg 2009; 35:875.</a></li><li><a class="nounderline abstract_t">Kaymen AH, Nasr A, Grekin RC. The use of carbon dioxide laser in lichen myxedematosus. J Dermatol Surg Oncol 1989; 15:862.</a></li></ol></div><div id="topicVersionRevision">Topic 89048 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23453242" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23453242" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908401" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17113967" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32027747" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31008568" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical and Molecular Phenotyping in Scleromyxedema Pretreatment and Posttreatment With Intravenous Immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31912592" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Increased frequency of interleukin-4 and reduced frequency of interferon-γand IL-17-producing CD4+ and CD8+ cells in scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493100" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Complete remission of scleromyxedema following autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/622555" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lichen myxedematosus serum stimulates human skin fibroblast proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2778769" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3981505" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22429092" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21831425" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Response to bortezomib of a patient with scleromyxedema refractory to other therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12810524" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Granulomatous reaction after intradermal injections of hyaluronic acid gel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422070" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Coma associated with scleromyxoedema and interferon alfa therapy. Full recovery after steroids and cyclophosphamide combined with plasmapheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22515222" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11552085" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The neurologic complications of scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19249127" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8275591" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Scleromyxedema associated with arthritis and myopathy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4071104" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Erosive arthropathy associated with scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3056423" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Scleromyxedema myopathy: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11251573" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Scleromyxedema (lichen myxedematosus) associated with dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2531729" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Scleromyxedema and severe myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12243709" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12581140" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Scleromyxedema revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20977988" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cardiomyopathy in scleromyxedema: report of a fatal case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260022" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lichen myxoedematosus with associated cardiac abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7601944" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204366" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134580" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : [Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1902938" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Laryngeal involvement in scleromyxedema: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21869708" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Scleroderma renal crisis-like acute renal failure associated with mucopolysaccharide accumulation in renal vessels in a patient with scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486700" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fatal scleromyxedema: report of a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11568755" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lichen myxedematosus with systemic involvement: clinical and autopsy findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10767707" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Scleromyxedema with dermato-neuro syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34778497" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : SARS-CoV-2: A potential trigger of dermato-neuro syndrome in a patient with scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26175017" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Does dermatoneuro syndrome have a viral aetiology?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33909318" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Two patients with dermatoneuro syndrome after influenza A infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22162593" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Scleromyxedema: a cutaneous paraneoplastic syndrome associated with thymic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10767692" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Scleromyxedema: possible association with seminoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28831414" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Paraneoplastic atypical scleromyxedema with advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/88953" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Spontaneous resolution of lichen myxoedematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11391115" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cutaneous mucinoses: microscopic criteria for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174386" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10380049" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sweat gland proliferations in scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26676919" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Frequency of cutis laxa-like clinical features and elastolysis in scleromyxedema: a retrospective clinicopathologic study of 19 patients with scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19638067" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26897387" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Histopathologic characteristics of scleromyxedema: A study of a series of 34 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23681113" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28370513" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7059207" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Papular mucinosis. A clinicopathologic study of four patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9816405" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : [Significance of histopathologic analysis of skin lesions in scleromyxedema. Light microscopy, electron microscopy, immunohistochemistry and immunofluorescence microscopy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31193003" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Dermoscopy and reflectance confocal microscopy for the diagnosis of scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20518147" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : [A cutaneous thickening case...].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28712039" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28712039" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28786499" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11161202" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16391408" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Intravenous immunoglobulin and fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17373996" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22278389" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779761" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Intravenous immunoglobulins control scleromyxoedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18583794" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20232589" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17854360" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/813582" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10319080" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Scleromyxedema: a complete response to prednisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16620228" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Scleromyxedema: An experience using treatment with systemic corticosteroid and review of the published work.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16198811" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : High-dose dexamethasone in scleromyxedema: report of 2 additional cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15280830" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18221985" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15243538" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23231733" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Successful treatment of scleromyxedema with oral thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17191049" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Scleromyxedema: successful treatment with thalidomide in two patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16902294" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Scleromyxedema, a positive effect with thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18312333" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Scleromyxedema--thalidomide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062103" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Successful treatment of scleromyxedema using thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23866873" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22404151" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21719421" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649597" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Fever, convulsions and coma in scleromyxedema: a "dermato-neuro syndrome".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22026006" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1952989" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Regression of scleromyxedema with topical betamethasone and dimethyl sulfoxide: a 30-month follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1599285" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Discrete papular mucinosis responding to intralesional and topical steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2050852" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Improvement of scleromyxedema associated with isotretinoin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3170809" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Scleromyxedema: therapeutic response to isotretinoin in three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025854" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Scleromyxedema: treatment with interferon alfa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657639" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Successful treatment of intractable scleromyxedema with cyclosporin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394362" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Successful treatment of scleromyxedema with dexamethasone cyclophosphamide pulse therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20101325" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Arndt Gottron scleromyxedema: successful response to treatment with steroid minipulse and methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1577603" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : [Arndt-Gottron scleromyxedema. Case report and review of therapeutic possibilities].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8698907" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Treatment of scleromyxedema with 2-chlorodeoxyadenosine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9591822" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Worsening of lichen myxedematosus during interferon alfa-2a therapy for chronic active hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888135" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Phototherapy and photochemotherapy of sclerosing skin diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3086390" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Scleromyxedema associated with scleroderma renal disease and acute psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17651175" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Scleromyxedema: treatment of widespread cutaneous involvement by total skin electron-beam therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7560458" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A case of lichen myxedematosus with clearly exacerbated skin eruptions after UVB irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24999269" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Allogeneic stem cell transplantation for the treatment of refractory scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29214719" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Ineffectiveness of infliximab CT-P13 for the treatment of scleromyxedema: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389090" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Surgical treatment of facial disfigurement due to lichen myxedematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2754090" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The use of carbon dioxide laser in lichen myxedematosus.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
